IL17A and inflammatory bowel disease: Particularly, IL-17 pathway blockade, but not IL-23 cytokine blockade, has been shown to impact the entire spectrum of osteoarticular pathology; however, IL-17 inhibition has been linked to flares in inflammatory bowel disease (IBD) (1–3).